OtherClinical Investigations (Human)
177Lu-EB-PSMA radioligand therapy with escalating doses in patients with metastatic castration-resistant prostate cancer
Jie Zang, Qingxing Liu, Huimin Sui, Rongxi Wang, Orit Jacobson, Xinrong Fan, Zhaohui Zhu and Xiaoyuan Chen
Journal of Nuclear Medicine May 2020, jnumed.120.242263; DOI: https://doi.org/10.2967/jnumed.120.242263
Jie Zang
1 Peking Union Medical College Hospital, China;
Qingxing Liu
2 Peking Union Medical University Hospital, China;
Huimin Sui
1 Peking Union Medical College Hospital, China;
Rongxi Wang
1 Peking Union Medical College Hospital, China;
Orit Jacobson
3 National Institutes of Health, United States
Xinrong Fan
1 Peking Union Medical College Hospital, China;
Zhaohui Zhu
1 Peking Union Medical College Hospital, China;
Xiaoyuan Chen
3 National Institutes of Health, United States

Article Figures & Data
Additional Files
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 66, Issue 5
May 1, 2025
177Lu-EB-PSMA radioligand therapy with escalating doses in patients with metastatic castration-resistant prostate cancer
Jie Zang, Qingxing Liu, Huimin Sui, Rongxi Wang, Orit Jacobson, Xinrong Fan, Zhaohui Zhu, Xiaoyuan Chen
Journal of Nuclear Medicine May 2020, jnumed.120.242263; DOI: 10.2967/jnumed.120.242263
177Lu-EB-PSMA radioligand therapy with escalating doses in patients with metastatic castration-resistant prostate cancer
Jie Zang, Qingxing Liu, Huimin Sui, Rongxi Wang, Orit Jacobson, Xinrong Fan, Zhaohui Zhu, Xiaoyuan Chen
Journal of Nuclear Medicine May 2020, jnumed.120.242263; DOI: 10.2967/jnumed.120.242263